• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Psychotropics in Pregnancy and Breastfeeding

Psychotropics in Pregnancy and Breastfeeding

November 1, 2010
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP
As a pharmacist specializing in psychopharmacology, I am commonly consulted by psychiatrists to provide updated information on the safety of medications in pregnancy and breastfeeding. It is a difficult task, because the quantity and quality of data for medications vary greatly. I developed the accomanpanying table for TCPR readers by pulling together a variety of sources, including isolated case reports, case series, birth registries, retrospective surveys, prospective comparative cohort studies, case control studies, and meta-analyses. Making judgments about which medication to use—or not use—in pregnant or lactating women is a delicate balancing act, involving an assessment of the severity of the underlying illness versus the uncertainties inherent in prescribing medications when the available data are limited.

In reading the following table, keep the following in mind: In the general U.S. population, the baseline rate of major malformations is between one and four percent, depending on the population studied and the definitions of “malformations” used. If treatment is necessary, monotherapy with the lowest effective dose and for the shortest duration is prudent. Safety data is generally more robust with older agents, which are more preferable to use than newer agents with less established safety profiles.

Almost all drugs will enter breast milk. The exposure to the infant is described as a percentage of the maternal dose—that is, how much of the dose is actually excreted into the breast milk. When less than 10% of a mother’s dose of medication is excreted into the breast milk, it is generally considered compatible with breastfeeding (with some exceptions) since these low serum levels are unlikely to lead to adverse effects in the infant.

For more information, I recommend checking out the websites for Motherisk, a resources for professionals and patients, at www.motherisk.org (see “Drugs in Pregnancy” and “Breastfeeding and Drugs” links); and LactMed database of the National Library of Medicine at http:// bit.ly/dybfhM.

See comprehensive psychotropics in pregnancy and breastfeeding chart here.

Additional References:
Cohen LS et al, Psychiatr Clin N Am 2010;33(2):273–293
Einarson A, Can J Clin Pharmacol 2009;16(1):e58–e65
Gentile S, Schizophrenia Bulletin 2010;36(3):518–544
Menson SJ, Arch Gynecol Obstet 2008;277:1–13
Myla ME, Can J Clin Pharmacol 2009;16(1):e49–e57
Yonkers KA et al, General Hospital Psychiatry 2009;31(5):403–413
General Psychiatry
www.thecarlatreport.com
Issue Date: November 1, 2010
SUBSCRIBE NOW
Table Of Contents
Antidepressant Treatment in Pregnancy: An Update
Psychotropics in Pregnancy and Breastfeeding
Current APA/ACOG Recommendations for Managing Depression during Pregnancy in Three Scenarios
The Motherisk Program
Antidepressant Response Not Linked to Serotonin Transporter Gene
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.